Zhenyu Hou
Key Laboratory Of Cancer Prevention And Therapy
Tianjin, 300060, China
Tianjin, 300060, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Drug-related adverse events potentially predict the efficacy of apatinib on advanced hepatocellular carcinoma.
Journal: BMC gastroenterology
Published: December 16, 2021
The Neutrophil-to-Lymphocyte Ratio (NLR) Predicts the Prognosis of Unresectable Intermediate and Advanced Hepatocellular Carcinoma Treated with Apatinib.
Journal: Cancer management and research
Published: March 29, 2021
Apatinib as first-line treatment in patients with advanced hepatocellular carcinoma: a phase II clinical trial.
Journal: Annals of translational medicine
Published: November 04, 2020
Resection of "down-staged" advanced hepatocellular carcinoma after treatment with the VEGFR2 inhibitor apatinib: five cases report.
Journal: Translational cancer research
Published: December 31, 2019
Drug-Related Hypertension Associated with the Efficacy of Apatinib on Hepatocellular Carcinoma.
Journal: Cancer management and research
Published: November 29, 2019
Apatinib is effective for treatment of advanced hepatocellular carcinoma.
Journal: Oncotarget
Published: May 24, 2017
Down-expression of poly(ADP-ribose) polymerase in p53-regulated pancreatic cancer cells.
Journal: Oncology letters
Published: June 19, 2016
Exploration of the value of MRCP combined with tumor marker CA19-9 in the diagnosis of pancreatic cancer.
Journal: Artificial cells, nanomedicine, and biotechnology
Published: December 05, 2014
Correlation and malignant transformation of MSCs with the overexpression of SIL-R/GP130 under the tumor microenvironment.
Journal: Medical oncology (Northwood, London, England)
Published: October 31, 2014
Showing 1-10 of 10
Last Updated: 09/26/2026